Lia DeGroot

Em­ploy­ers who of­fer in­sur­ance cov­er­age of the new class of obe­si­ty med­ica­tions could dou­ble next year, ac­cord­ing to a new sur­vey of 500 em­ploy­ers. Con­duct­ed

Cal­i­for­nia Gov. Gavin New­som ve­toed a bill that would have capped in­sulin prices at $35 per month, cit­ing his ex­ist­ing plan to make Cal­i­for­nia’s own

Cov­er­ing an­ti-obe­si­ty med­ica­tions through Medicare would sig­nif­i­cant­ly in­crease fed­er­al spend­ing, the Con­gres­sion­al Bud­get Of­fice said in an analy­sis pub­lished Thurs­day con­clud­ing that more re­search is

The Rea­gan-Udall Foun­da­tion on Thurs­day pub­lished a wide-rang­ing re­port on how the FDA can com­bat mis­in­for­ma­tion, mark­ing some progress on one of FDA Com­mis­sion­er Robert

A group of more than 30 life sci­ences or­ga­ni­za­tions, in­clud­ing gi­ants Am­gen, Gilead and Mer­ck, has band­ed to­geth­er to push back against an­titrust re­form ef­forts

A fed­er­al judge on Fri­day up­held the Medicare drug price ne­go­ti­a­tion pro­vi­sions of the In­fla­tion Re­duc­tion Act, block­ing an ef­fort by the Cham­ber of Com­merce

The FDA on Fri­day un­veiled a long-await­ed pro­posed rule that aims to over­haul how the agency reg­u­lates di­ag­nos­tic tests, bring­ing thou­sands of new tests un­der

The fed­er­al gov­ern­ment is brac­ing for a shut­down if law­mak­ers on Capi­tol Hill can’t ral­ly enough votes to keep the gov­ern­ment fund­ed by the end

The Biden ad­min­is­tra­tion is pump­ing $100 mil­lion in­to a re­search project fo­cused on com­bat­ing the threat of drug-re­sis­tant bac­te­ria, the Ad­vanced Re­search Projects Agency for

The FDA is re­open­ing the com­ment pe­ri­od on its dis­cus­sion pa­per on us­ing ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment, co­in­cid­ing with a two-day work­shop on the